Cyclacel Pharmaceuticals (NASDAQ:CYCC) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Capital lowered shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Trading Up 1.2 %

CYCC stock opened at $0.42 on Friday. The stock has a 50-day moving average price of $0.39 and a two-hundred day moving average price of $0.94. Cyclacel Pharmaceuticals has a 1 year low of $0.31 and a 1 year high of $4.00. The stock has a market cap of $2.64 million, a PE ratio of -0.04 and a beta of 0.35.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.36. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. On average, analysts forecast that Cyclacel Pharmaceuticals will post -1.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 23.58% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.